Clinical Scorecard: Analysis of Midbrain and Pons Morphology via MRI and Its Clinical and CSF Associations in Neurodegenerative Parkinsonisms: A Preliminary Investigation
At a Glance
Category
Detail
Condition
Neurodegenerative parkinsonisms including Parkinson’s disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD)
Key Mechanisms
Brainstem atrophy patterns (midbrain and pons) detected by structural MRI and shape analysis; CSF neurofilament-light chain (NfL) biomarker correlations
Target Population
Patients with clinically established or probable neurodegenerative parkinsonisms and age-matched controls over 55 years without neurological or psychiatric conditions
Care Setting
Movement Disorders specialized neurology units with access to high-field MRI and CSF analysis
Key Highlights
Midbrain atrophy is characteristic in PSP, while pontine atrophy is typical in MSA, detectable via MRI morphological markers and quantitative measures.
Shape analysis of brainstem MRI offers local atrophy detection beyond volumetric measures and may differentiate neurodegenerative parkinsonisms.
CSF neurofilament-light chain (NfL) levels correlate with brainstem morphological changes and clinical severity in these disorders.
Guideline-Based Recommendations
Diagnosis
Use structural MRI to assess midbrain and pons morphology for differential diagnosis of PD, PSP, MSA, and CBD.
Apply shape analysis techniques to detect local brainstem atrophy patterns for improved diagnostic specificity.
Incorporate CSF NfL biomarker measurement to support clinical and imaging findings.
Management
Perform comprehensive clinical assessments including motor scales (UPDRS, UMSARS, PSPRS) and cognitive screening (MoCa or MMSE).
Use MRI and CSF biomarkers to monitor disease progression and guide clinical decision-making.
Monitoring & Follow-up
Repeat MRI brainstem morphometry and CSF NfL measurements longitudinally to track neurodegeneration.
Assess functional disability using scales such as Schwab and England Activities of Daily Living (SEADL).
Risks
Exclude vascular or drug-induced parkinsonism and Alzheimer’s disease CSF biochemical profiles to avoid diagnostic confounders.
Ensure MRI acquisition protocols are standardized to maintain measurement reliability.
Patient & Prescribing Data
Patients diagnosed with neurodegenerative parkinsonisms undergoing MRI and CSF biomarker evaluation
No direct treatment data reported; imaging and CSF biomarkers assist in diagnosis and monitoring rather than guiding pharmacologic therapy.
Clinical Best Practices
Obtain high-field 3-T MRI with standardized T1-weighted 3D-MPRAGE sequences for brainstem morphometry.
Collect CSF samples via lumbar puncture under standardized conditions and measure NfL using validated ELISA kits.
Use automated and manual methods to quantify midbrain and pontine areas and calculate pons-to-midbrain ratios.
Perform detailed clinical phenotyping with validated motor and cognitive scales specific to each parkinsonism subtype.
Exclude confounding conditions through clinical history, imaging, and CSF biochemical profiles.
by C. Painous, S. Pascual-Diaz, E. Muñoz-Moreno, V. Sánchez, JC. Pariente, A. Prats-Galino, M. Soto, M. Fernández, A. Pérez-Soriano, A. Camara, E. Muñoz, F. Valldeoriola, N. Caballol, C. Pont-Sunyer, N. Martin, M. Basora, M. Tio, J. Rios, MJ. Martí, N. Bargalló, Y. Compta
Diagnosing Parkinson’s disease has long depended primarily on clinical expertise — careful neurologic examination, longitudinal symptom assessment and the nuanced interpretation of movement abnormalities.
